Table 1 summarizes the sociodemographic, clinical and treatment characteristics of the whole sample, including the type of hepatitis, the prescribed medication, the dosage of IFN-α, the duration of IFN-α therapy, and the frequency of treatment success for the examined drug-free subgroup. This evidence concerns the gene IFNA17 and hepatitis A virus infection.